Hologic, Inc. (NASDAQ:HOLX) Short Interest Update

Hologic, Inc. (NASDAQ:HOLX) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 5,930,000 shares, an increase of 5.9% from the January 15th total of 5,600,000 shares. Based on an average trading volume of 2,310,000 shares, the short-interest ratio is presently 2.6 days. Currently, 2.7% of the company’s stock are short sold.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hologic

Several institutional investors have recently modified their holdings of HOLX. General Partner Inc. acquired a new stake in Hologic during the 4th quarter worth approximately $26,000. Groupama Asset Managment increased its position in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC increased its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 261 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 260 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.1 %

NASDAQ:HOLX traded up $0.68 during trading hours on Tuesday, hitting $63.92. The stock had a trading volume of 1,969,437 shares, compared to its average volume of 2,519,579. The business’s 50 day moving average is $70.53 and its 200-day moving average is $76.91. The company has a market cap of $14.43 billion, a price-to-earnings ratio of 20.16, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic has a one year low of $62.69 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts anticipate that Hologic will post 4.27 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on HOLX shares. Stephens reissued an “overweight” rating and set a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Jefferies Financial Group assumed coverage on shares of Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target on the stock. Raymond James restated an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.